{"id":"NCT00419341","sponsor":"CSL Behring","briefTitle":"Study of Subcutaneous Immunoglobulin in Patients With PID Requiring IgG Replacement Therapy","officialTitle":"A Phase III Open-Label, Prospective, Multicenter Study of the Efficacy, Tolerability, Safety, and Pharmacokinetics of Immune Globulin Subcutaneous (Human), IgPro20 in Subjects With Primary Immunodeficiency (PID)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-11","primaryCompletion":"2008-10","completion":"2008-10","firstPosted":"2007-01-08","resultsPosted":"2013-01-25","lastUpdate":"2013-01-25"},"enrollment":49,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Primary Immune Deficiency"],"interventions":[{"type":"BIOLOGICAL","name":"Human Normal Immunoglobulin for Subcutaneous Administration","otherNames":["Hizentra"]}],"arms":[{"label":"IgPro20","type":"EXPERIMENTAL"}],"summary":"The objective of this study is to assess the efficacy, tolerability, safety and pharmacokinetics of IgPro20 in patients with primary humoral immunodeficiency (PID).","primaryOutcome":{"measure":"Annualized Rate of Clinically Documented Serious Bacterial Infections (SBIs) (MITT Population)","timeFrame":"Efficacy period: up to 12 months (week 13 to the completion visit)","effectByArm":[{"arm":"IgPro20","deltaMin":0,"sd":null}],"pValues":[]},"eligibility":{"minAge":"2 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":14},"locations":{"siteCount":13,"countries":["United States"]},"refs":{"pmids":["20454851","21553933"],"seeAlso":["http://www.ncbi.nlm.nih.gov/pubmed/20454851"]},"adverseEventsSummary":{"seriousAny":{"events":7,"n":49},"commonTop":["Injection site reaction","Sinusitis","Headache","Nasopharyngitis","Cough"]}}